Business
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina\n\n\n\n MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina. Knight obtained approval from the Argentinian health regulatory agency, ANMAT, for MINJUVI® (tafasitamab) in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT).\n \n\n DLBCL is the most common subtype of non-Hodgkin lymphoma, presenting an aggressive clinical profile. While a significant number of patients can be cured with standard front-line therapy, many will develop refractory disease or relapse following an initial response, and these individuals are often ineligible for ASCT. Such patients face a very poor prognosis, emphasizing the need for treatment options to improve their outcomes\n \n 1\n \n .\n \n\n The approval is based on the data from L-MIND trial, an open label, multicenter, single arm Phase 2 study, that evaluated MINJUVI® in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL ineligible for ASCT. The primary analysis results demonstrated an objective response rate (ORR, primary endpoint) of 60%, including a complete response rate (CR) of 43% and a disease control rate (DCR) of 74%\n \n 2\n \n\n ,3\n \n . According to the 2024 National Comprehensive Cancer Network (NCCN) Guidelines, MINJUVI® is listed as one of the preferred second-line treatments for DLBCL patients who are ineligible for transplantation\n \n 4\n \n .\n \n\n “MINJUVI® has a unique and innovative mechanism of action targeting CD19 and represents a significant advancement in the treatment of DLBCL. It is a targeted immunotherapy which offers sustained remission for non-transplant eligible adult patients who have relapsed or are refractory to at least one previous line of treatment. I am enthusiastic about the transformative potential of MINJUVI® in improving patient outcomes,ȁ...